Articles On Adalta (ASX:1AD)
Title | Source | Codes | Date |
---|---|---|---|
Closing Bell: ASX drops, and a waste management stock gets takeover offer
The ASX 200 dropped 0.30% and the ASX XEC declined 0.20% Only 4 out of 11 sectors were higher, with Utilities leading the way Waste management company M8 Sustainable receives unsolicited takeover offer The ASX 200 declined 0.30% today,... |
Stockhead | 1AD | 1 year ago |
AdAlta (ASX:1AD) welcomes Yuuwa as new substantial shareholders
AdAlta (1AD) welcomes two new investors associated via the Yuuwa Capital Venture Capital fund as substantial shareholders The company says support from Yuuwa and major shareholders has enabled AdAlta’s continued pipeline progress and has... |
themarketherald.com.au | 1AD | 1 year ago |
Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device
Japanese startup OUI is on a mission to halve the world’s blindness with its smartphone-based device Which ASX healthcare companies also have smartphone-based products? A quick look at the best and worst ASX healthcare stocks over the past... |
Stockhead | 1AD | 1 year ago |
ASX Health Stocks: MGC Pharma passes final hurdle before FDA submission; patents for Recce and AdAlta
MGC Pharma completes pre-clinical study on CimetrA Recce Pharma close to getting Aussie patent AdAlta gets second patent in Japan MGC Pharma on track for FDA submission MGC Pharma (ASX:MXC) has completed the full pre-clinical rodents st... |
Stockhead | 1AD | 1 year ago |
AdAlta (ASX:1AD) receives second Japanese patent for AD-214
AdAlta (1AD) has been granted its second patent by the Japanese Patent Office for its lead program, AD-214 The company says the patent is a “valuable” addition as it will support the expansion of protected claims for AD-214 in Japan whic... |
themarketherald.com.au | 1AD | 1 year ago |
Market Highlights: Fed comments scare the market, and 5 ASX small caps to watch on Tuesday
The ASX will open marginally lower on Tuesday Overnight, Wall Street was mixed but turned negative after comments from US Fed policymakers Oil prices rose another 1pc Aussie shares will open marginally lower this morning, and at 8am AED... |
Stockhead | 1AD | 1 year ago |
Top 10 at 10: Which lithium stock leads the winners list on Friday?
Stockhead’s Top 10 at 10, published shortly after 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the bigg... |
Stockhead | 1AD | 1 year ago |
How out of favour Biotech has a PR problem and could learn from Dr Karl
ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and... |
Stockhead | 1AD | 1 year ago |
ASX Biotech Stocks: HitIQ nabs landmark deal with Premier League for its concussion management tech
HitIQ has entered into a two-year deal with the Premier League for its concussion management tech Hearing-aid manufacturer Nuheara has been awarded two US patents Argentica Therapeutics moves to second escalated dose cohort for its stroke... |
Stockhead | 1AD | 1 year ago |
Market Highlights: US and Euro shares on six-day losing streak, and 5 ASX small caps to watch on Thursday
The ASX will open lower on Thursday US and European sharemarkets are on a six-day losing streak Minutes from FOMC show that Fed officials expect rates to remain high Local shares are set to open slightly lower on Thursday. At 8am AEST, th... |
Stockhead | 1AD | 1 year ago |
Check Up: Blood clots are a $55bn opportunity and these 2 ASX stocks are vying for a slice
Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re... |
Stockhead | 1AD | 1 year ago |
Dr Boreham’s Crucible: Is Vectus Biosystems about to become a VIP for takeover suitors?
As with almost every other drug developer on the planet, Vectus Biostsyems (ASX:VBS) co-founder Maurie Stang believes his fibrotic diseases outfit is of interest to potential, deep-pocketed partners. The difference is that given his life sc... |
Stockhead | 1AD | 1 year ago |
Twiggy’s Tattarang is getting into health tech – which ASX stocks will benefit?
Twiggy’s Tattarang has seeded a new fund called Tenmile with $250m Tenmile will focus mainly on Aussie biotechs Here are the ASX stocks that will benefit Andrew “Twiggy” Forrest’s business philosophy has always been: “You bite off more th... |
Stockhead | 1AD | 1 year ago |
Check Up: US FDA approves first clinical trial of naturally derived psychedelic drugs
US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F... |
Stockhead | 1AD | 1 year ago |
Check Up: These biotech themes got billions in VC funding. These ASX stocks could benefit
A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m... |
Stockhead | 1AD | 1 year ago |
AdAlta (ASX:1AD) granted European patent for AD-124
AdAlta (1AD) receives a European patent from the European Patent Office for its lead product AD-124 The patent is titled “CXCR4 binding molecules” and has an expiry date of January 8, 2036 It protects the i-body sequence used in AD-214, s... |
themarketherald.com.au | 1AD | 1 year ago |
Market highlights and 5 ASX small caps to watch on Tuesday
The ASX 200 is set to open 4% lower today Wall Street crashes following higher than expected inflation report on Friday Bitcoin plunges 13% The ASX is poised to crash by more than 4% at the open this morning after another plunge in Wall S... |
Stockhead | 1AD | 1 year ago |
Check Up: Money managers are still bullish on Healthcare; here’s what they said
The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week Dr Anthony Faucci, America’s top infectious disea... |
Stockhead | 1AD | 1 year ago |
Check Up: Biotechs are going through a rough patch, but recent ASX IPOs haven’t flopped too badly
The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot... |
Stockhead | 1AD | 1 year ago |
CBA, NAB, ANZ: Why are these banking stocks in news in April?
Highlights Today, the S&P/ASX 200 Financial sector (ASX:XFJ) traded approximately 0.843% lower at 6730.100 points at 12:06 PM AEDT. The benchmark index ASX200 was trading 0.528% lower at 7450.600 points at 11:23 AM AEST. Three ASX... |
Kalkine Media | 1AD | 1 year ago |
AdAlta (ASX:1AD) bags first Indian patent for i-body technology platform
Highlights AdAlta’s lead i-body candidate AD-214 has bagged its first Indian patent. The patent entitled “CXCR4 binding molecules” is valid till 08 January 2036 AdAlta aims to partner with other biopharmaceutical companies to maximise... |
Kalkine Media | 1AD | 1 year ago |
ASX Health Stocks: AdAlta gets patent in India, RhinoMed starts selling in Canada
AdAlta gets first patent in India RhinoMed to start selling Covid swaps and RAT kits in Canada AdAlta (ASX:1AD) has received an Indian patent for its lead program, AD-214. The new patent protects the i-body sequence used in AD-214, as wel... |
Stockhead | 1AD | 1 year ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
The US Fed plans to reduce its bond back by US$95bn a month Nasdaq plunged another 2% ASX to open lower this morning Wall Street skids on US Fed’s plan Aussie shares are poised to follow Wall Street into the red today, with the ASX 200 Ap... |
Stockhead | 1AD | 1 year ago |
Check Up: More clinical trials and FDA funding boost. Is this the end of biotech’s woes?
Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve... |
Stockhead | 1AD | 1 year ago |
ASX Health Stocks: Cannabis biotech Emyria all set for Phase 1 clinical trial of lead CBD drug
The ASX 200 Health Index (XHJ) is up by 0.30% at the time of writing, compared to the broader index which is up by 0.60%. Clinical stage cannabis biotech, Emyria (ASX: EMD), announced that participant recruitment, screening and consenting h... |
Stockhead | 1AD | 2 years ago |
Check Up: The future of telehealth, and the best and worst performing ASX health stocks for the month
Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal... |
Stockhead | 1AD | 2 years ago |
AdAlta (ASX:1AD) granted Chinese patent for AD-214 product
AdAlta (1AD) has been granted a patent for its lead product AD-214 by the China National Intellectual Property Administration The new patent protects the i-body sequence used in AD-214 and pharmaceutical compositions and diagnostic applica... |
themarketherald.com.au | 1AD | 2 years ago |
ASX Health Stocks: MVP’s ‘green whistle’ has finally got to Phase 3 in the US after FDA decision
The ASX 200 Health Index (XHJ) is trading lower by 0.27% at the time of writing, compared to the broader index which is falling by 0.56%. Pain relief specialist Medical Development International (ASX:MVP) announced that the US FDA has uncon... |
Stockhead | 1AD | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Wall Street tumbles, ASX to fall as oil prices spike Aussie shares are set to follow Wall Street into the red today, as oil prices surged by as much as 10% overnight. As fighting in the Ukraine intensified, the US and other major economies... |
Stockhead | 1AD | 2 years ago |
Check Up: Johnson & Johnson manoeuvre causes a stir, as CSL pulls Healthcare higher on the ASX
The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby... |
Stockhead | 1AD | 2 years ago |
Webinar Recap – TNR, LBT, 1AD & LIT
ShareCafeWebinar Recap – TNR, LBT, 1AD & LIT Catch up on the full webinar with presentations from Torian Resources (ASX: TNR), LBT Innovations (ASX: LBT), Adalta (ASX: 1AD) & Lithium Australia (ASX: LIT) Webinar Recap – TNR... |
ShareCafe | 1AD | 2 years ago |
AdAlta (ASX: 1AD) – Webinar Presentation
ShareCafeAdAlta (ASX: 1AD) – Webinar Presentation Tim Oldham – CEO and Managing Director – AdAlta is a clinical-stage biotechnology company that uses its i-body platform to discover and develop next-generation protein therapeutics addressi... |
ShareCafe | 1AD | 2 years ago |
Check Up: As Omicron rages, rapid antigen testing specialist Atomo surges nearly 50pc
At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform... |
Stockhead | 1AD | 2 years ago |
Check Up: Anteotech riding high with $1.9m refund, and Avecho inks supply agreement for CBD arthritis treatment
It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %... |
Stockhead | 1AD | 2 years ago |
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19 ravaged the world. Nasdaq-listed BioNTech, which... |
Stockhead | 1AD | 2 years ago |
Closing Bell: Energy and financial stocks fall sharply as the ASX starts the week on a downer
The ASX started the week lower as a result of a drop in the energy and financial sectors. Energy shares fell by over 3%, as surging cases of the Omicron variant raised fears that new restrictions may hit fuel demand. Financials meanwhile we... |
Stockhead | 1AD | 2 years ago |
AdAlta (ASX:1AD) gets commitments for $3.75m placement
Clinical-stage biotech company AdAlta (1AD) is looking to raise up to $5.95 million through a placement and non-renounceable entitlement offer The company received commitments from investors for the placement, which is raising $3.75 millio... |
themarketherald.com.au | 1AD | 2 years ago |
Closing Bell: Energy, resources and property lead the ASX as ‘Santa rally’ appears on track
The so-called ‘Santa Claus Rally’ appears to be happening again this year with the ASX notching another positive day. The ASX 200 closed at 7,379 points which was 0.35% higher than Friday, following on from a 1.6% gain last week and positiv... |
Stockhead | 1AD | 2 years ago |
Closing Bell: ASX edges lower ahead of all-important US inflation data
For the first time in over a month, the ASX finished a week higher than where it began — even with the bourse declining on an intraday basis. The ASX 200 closed at 7,353 points which was 0.42% lower than yesterday, but up 1.6% from last Fri... |
Stockhead | 1AD | 2 years ago |
AdAlta (ASX:1AD) enters trading halt following positive AD-214 outcomes
Clinical-stage drug developer AdAlta (1AD) has entered a trading halt while it plans and completes a capital raise 1AD recently announced positive outcomes from early testing of its AD-214 drug candidate which is being developed for future... |
themarketherald.com.au | 1AD | 2 years ago |
ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US
The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index which is down by 0.35%. Brain-focused company, Argenica Therapeutics (ASX:AGN), has just been awarded a US patent relating to the use of i... |
Stockhead | 1AD | 2 years ago |
Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables
It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont... |
Stockhead | 1AD | 2 years ago |
Check Up: Sustainable Nutrition riding high and Singular Health branches out from… health
It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining. Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M... |
Stockhead | 1AD | 2 years ago |
Market Highlights and 5 ASX Small Caps to watch on Thursday
Wall Street retreats overnight All three US stock market indexes retreated overnight, with the Dow Jones falling by 0.58% , the S&P 500 by 0.26%, and tech heavy Nasdaq by 0.33%. US retailer Target’s Q3 revenues smashed estimates, but co... |
Stockhead | 1AD | 2 years ago |
AdAlta announces transfer of BTB funding agreement to AD-214 inhaled program
AdAlta (ASX:1AD) has announced an amendment to its funding agreement with MTPConnect under the Australian Government’s MRFF’s Biomedical Translation Bridge program with the support of UniQuest. |
BiotechDispatch | 1AD | 2 years ago |
Closing Bell: ASX has its worst day since February, suffering 2.1pc drop
Australia’s bourse had its biggest decline since February 26 falling by over 2%. The ASX 200 fell 2.1% to close at 7,248 and is down 5% since August 13. The ASX Emerging Companies Index fared worse, losing over 4% in its worst day since Apr... |
Stockhead | 1AD | 2 years ago |
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat... |
Stockhead | 1AD | 2 years ago |
CAR-T therapy is potentially a $20bn market. Here’s how it works and the ASX players in the space
The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main... |
Stockhead | 1AD | 2 years ago |
ASX Announcement: AdAlta and Carina Biotech to develop next-generation CAR-T cancer therapeutics
Highlights: AdAlta and Carina Biotech enter a collaboration agreement to develop i-body enabled CAR-T cancer immunotherapies against up to five solid tumour antigen targets Combining Carina’s advanced CAR-T platform technologies with AdAl... |
FNArena | 1AD | 2 years ago |
Closing Bell: Energy shares push ASX higher
It was another positive close for the Australian bourse today with energy the standout sector. The ASX 200 closed 0.17% higher at 7,503 points while the ASX Emerging Companies Index gained 1.1% to close at 2,262 points. Leading the charge w... |
Stockhead | 1AD | 2 years ago |